B. Riley FBR analyst David Buck says Alkermes remains one of his firm’s “Favorite Five stocks” for the second half of 2018 following the company’s Q3 results. He reiterates a Buy rating on the shares with a $60 price target. The upcoming FDA Advisory Committee meeting on November 1 for antidepressant candidate ALKS 5461 is key focus for investors, Buck tells investors in a research note. Further, the analyst points out that while Vivitrol sales were a “bit softer” than modeled in Q3, he sees potential growth from continued federal support for opioid programs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.